- Home
- MFIN vs IPHA Comparison
MFIN vs IPHA Comparison
Compare MFIN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- IPHA
- Stock Information
- Founded
- MFIN 1995
- IPHA 1999
- Country
- MFIN United States
- IPHA France
- Employees
- MFIN N/A
- IPHA N/A
- Industry
- MFIN Finance: Consumer Services
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- MFIN Finance
- IPHA Health Care
- Exchange
- MFIN Nasdaq
- IPHA Nasdaq
- Market Cap
- MFIN 190.0M
- IPHA 148.3M
- IPO Year
- MFIN 1996
- IPHA 2019
- Fundamental
- Price
- MFIN $9.34
- IPHA $1.67
- Analyst Decision
- MFIN
- IPHA Strong Buy
- Analyst Count
- MFIN 0
- IPHA 1
- Target Price
- MFIN N/A
- IPHA $11.50
- AVG Volume (30 Days)
- MFIN 46.5K
- IPHA 58.1K
- Earning Date
- MFIN 02-18-2025
- IPHA 09-12-2024
- Dividend Yield
- MFIN 4.68%
- IPHA N/A
- EPS Growth
- MFIN N/A
- IPHA N/A
- EPS
- MFIN 1.69
- IPHA N/A
- Revenue
- MFIN $293,257,000.00
- IPHA $36,202,722.00
- Revenue This Year
- MFIN N/A
- IPHA N/A
- Revenue Next Year
- MFIN $10.95
- IPHA $101.65
- P/E Ratio
- MFIN $5.55
- IPHA N/A
- Revenue Growth
- MFIN 18.48
- IPHA N/A
- 52 Week Low
- MFIN $6.48
- IPHA $1.29
- 52 Week High
- MFIN $10.50
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- MFIN 47.60
- IPHA 41.98
- Support Level
- MFIN $8.74
- IPHA $1.60
- Resistance Level
- MFIN $9.56
- IPHA $1.87
- Average True Range (ATR)
- MFIN 0.29
- IPHA 0.13
- MACD
- MFIN -0.01
- IPHA -0.04
- Stochastic Oscillator
- MFIN 61.22
- IPHA 12.96
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. Its operating segments include recreation, home improvement, commercial lending, medallion lending and Corporate and Other Investments. The company generates maximum revenue from the Recreation segment.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.